STERIS plc

The four scores agree on the balance sheet picture but differ in how much attention the narrative needs. The Beneish M-Score is -2.589, below the -1.78 threshold, so it is not in the elevated manipulation-risk zone. This is a statistical screen, not proof that the figures are clean, so the sharp net income increase still deserves a careful read. The Altman Z-Score is 4.56, in the safe zone, which is a model estimate of financial distress risk rather than a guarantee. The Piotroski F-Score is 8 of 9 computable signals, a checklist of profitability, leverage, and efficiency tests. The Fog Index of 14.37 falls in the 14 to 18 band, meaning the MD&A is hard to read. On the balance sheet, total liabilities fell from $4.75 billion to $3.53 billion and long-term debt fell from $3.12 billion to $1.92 billion, while equity rose from $6.3 billion to $6.6 billion. The 10-Q shows that $150.0 million of the $500.0 million repurchase authorization from May 3, 2023 remained as of December 31, 2025. Readers may also want to note the Rule 10b5-1 trading plan adopted on November 19, 2025 by General Counsel J. Adam Zangerle, covering up to 16,003 ordinary shares and expiring March 15, 2027. Because Dental is now discontinued, current comparisons rest on the Healthcare, AST, and Life Sciences segments, and the filings provided do not break out segment-level results.

Catalyst.The FY2025 10-K and the 10-Q for the period ended December 31, 2025 describe three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment is now presented as discontinued operations. Fiscal 2025 revenue reached $5.46 billion, up 6.2% from $5.14 billion in fiscal 2024. Operating income rose to $866.64 million from $836.12 million, and operating cash flow reached $1.15 billion from $973.27 million. The business section links demand to an aging population, rising procedure volumes such as endoscopies and colonoscopies, and customers seeking greater efficiency. In the first nine months of fiscal 2026, the company repurchased 0.6 million shares for $150.0 million.

Hidden risk.The most easily missed tension is between net income and operating results. Net income rose to $614.64 million from $378.24 million, an increase of about 62.5%, while operating income grew only about 3.7%. The gap therefore comes from items below operating income that the provided data does not explain, and readers may want to check the income statement notes. Operating cash flow was 1.87 times net income for fiscal 2025. The MD&A Fog Index of 14.37 falls in the hard-to-read band. The filing also states that ethylene oxide and cobalt-60, both needed for AST operations, are single-sourced in certain regions under long-term supply contracts. The risk-factor excerpt provided is mostly a table of contents, so readers may want to read the full Item 1A.